Axi Innovation provides pharmaceutical, medtech, and gene therapy executives with the intelligence infrastructure to launch faster, navigate policy, reach patients, and outmanoeuvre the competition â across every market that matters.
Market access is becoming harder, not easier. The average time from drug approval to patient access reached 578 days in 2024 â and fewer than 46% of centrally approved medicines are now available to patients, down from 48% in 2019. Here's what that costs.
A single day of delayed market entry costs approximately $800K in lost specialty drug sales. Every month without access in a target market is $24M in revenue that never recovers.
The time from regulatory approval to actual patient access has now reached 578 days on average â nearly 20 months. That gap is growing, not shrinking.
One in three drugs launched between 2012â2021 missed their revenue targets â with 57% of those failures attributable directly to limited market access.
More than $300B in global treatment value is destroyed each year by prescription abandonment and non-adherence â up to 69% abandonment for specialty drugs with high out-of-pocket costs.
Up to 40% of Health Technology Assessment submissions face rejection or restrictions in major markets â each failed submission adds 18+ months before a re-attempt is possible.
Market share shifts happen 6â18 months before companies detect them. Without real-time intelligence, organisations are always repositioning too late â losing windows that never reopen.
Every module was designed to close a specific intelligence gap that costs pharmaceutical, medtech, and gene therapy companies revenue, positioning, and patients. Click any module to explore pricing.
Each month of delayed market entry costs an estimated $24M in lost revenue. Only 40% of products reach 5+ markets within 24 months of first approval.
Real-time payer landscapes, distributor readiness, pricing windows, and regulatory pathway intelligence â so your launch sequence is deliberate, swift, and commercially protected across all target geographies.
A single missed regulatory update can delay or block market access for 12â18 months. Manual monitoring of 80+ agencies is operationally unsustainable.
Automated surveillance of 80+ global health authorities with AI-powered alerts on legislation, reimbursement policy shifts, and advocacy windows â so your government affairs teams are perpetually ahead of the curve.
Up to 69% of specialty prescriptions are abandoned before first fill. More than $300B in treatment value is lost annually to non-adherence and access barriers.
End-to-end patient navigation covering prior authorisation, co-pay support, adherence monitoring, and real-world evidence generation â protecting patient outcomes and commercial returns simultaneously.
Market share shifts happen 6â18 months before companies detect them. Reactive intelligence means responding too late â wasting spend and ceding positioning windows.
Dedicated, organisation-specific competitive intelligence â custom market models, real-time share tracking, and forward-looking scenario planning â aligned to your therapeutic area, geography, and strategic priorities.
Up to 40% of HTA submissions are restricted or rejected. P&R delays rank among the top five negative business factors cited by senior pharma executives.
Real-time public market intelligence across 30+ healthcare systems â reimbursement decisions, payer policy feeds, and competitive positioning data â so access teams never negotiate underprepared.
A failed HTA submission forces a restart. Second submissions add 18+ months â with incomplete economic models the leading cause of outright rejection.
Full-cycle HEOR support: economic modelling, budget impact analysis, value dossier development, and local payer alignment strategy â engineered for first-submission success across all target markets.
Axi Innovation was founded to close the intelligence gap between regulatory approval and patient access â the critical window where commercial value is won or lost, where competitive positioning is established, and where patients either reach treatment or fall through the cracks.
We work exclusively with pharmaceutical, medtech, and gene therapy executives who operate at corporate, regional, and local scale â and who require intelligence that moves as fast as their markets do.
Six intelligence modules in one environment. No fragmented vendor stack. No blind spots.
Continuous monitoring of agencies, markets, and competitive signals â insights in hours, not quarters.
Intelligence that traces from payer decision to patient outcome â closing the commercial-clinical loop.
Enterprise-grade data governance. Your intelligence is yours â never shared, never leveraged.
We are selectively onboarding partners across pharmaceutical, medtech, and gene therapy sectors. Tell us about your market access challenge.